ACM
AIMT

Atika Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Atika Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-98,000
Closed -$3.12M – 106
2018
Q1 		$3.12M Buy
98,000
+13,000
+15% +$457K 1.07% 39
2017
Q4 		$3.21M Buy
+85,000
New +$2.74M 1.24% 37

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Atika Capital Management's AIMT Position: Q2 2018 in Review

Atika Capital Management sold out of Aimmune Therapeutics (AIMT) in Q2 2018, closing a stake of 98,000 shares — an estimated $3.12M sold.

Atika Capital Management first reported a position in AIMT in Q4 2017 and held it in 2 quarters. The position peaked at $3.21M in Q4 2017. 151 funds tracked by Wall St. Rank hold AIMT as of Q2 2018.

  • Atika Capital Management reported no remaining Aimmune Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Atika Capital Management sold 98,000 Aimmune Therapeutics shares in Q2 2018, an estimated $3.12M.
  • Atika Capital Management first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 2 quarters.
  • Atika Capital Management's Aimmune Therapeutics position peaked at $3.21M in Q4 2017.
  • 151 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2018.

Based on Atika Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.